Table 1.
Key clinical trials assessing the efficacy of BRAFi in melanoma patients.
| Clinical trial | ORR | Median PFS (Months) |
Median OS (Months) |
Treatment arms (number of patients) |
Reference |
|---|---|---|---|---|---|
| BRIM-3 | 57% 9% |
6.9 1.6 |
13.6 9.7 |
Vemurafenib*
Dacarbazine⁑ |
(63) |
| BREAK-3 | 50% 6% |
6.9 2.7 |
20 15.6 |
Dabrafenib*
Dacarbazine |
(64, 65) |
| METRIC | 19% 5% |
4.9 1.6 |
15.6 11.3 |
Trametinib*
Chemotherapy |
(66, 67) |
| COMBI-v | 68% 53% |
12.1 7.3 |
26 17.8 |
Dabrafenib + Trametinib†
Vemurafenib |
(68) |
| COMBI-d | 70% 54% |
10.2 8.8 |
25.8 18.7 |
Dabrafenib + Trametinib Dabrafenib |
(69) |
| COMBI-i | 68.5 64.2 |
16.2 12 |
Not Specified | Spartalizumab‡ + Dabrafenib + Trametinib Dabrafenib + Trametinib |
(70) |
| coBRIM | 70% 50% |
12.6 7.2 |
22.5 17.4 |
Vemurafenib + Cobimetinib†
Vemurafenib |
(71) |
| COLUMBUS | 63% 51% 40% |
14.9 9.6 7.3 |
33.6 23.5 16.9 |
Encorafenib* + Binimetinib†
Encorafenib Vemurafenib |
(72–74) |
*BRAFi; ⁑Chemotherapy; †MEKi; ‡Anti-programmed cell death protein-1 (PD-1).
This table summarizes key clinical trials investigating the roles of BRAFi in patients with melanoma, including the ORR, PFS, and OS outcomes.